NEW YORK, August 5, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding LyondellBasell Industries NV (NYSE: LYB), Whiting Petroleum Corp (NYSE: WLL), Albemarle Corporation (NYSE: ALB), Baker Hughes Incorporated (NYSE: BHI) and Noble Energy Inc (NYSE: NBL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5440-100free.
--
LyondellBasell Industries NV Research Reports
On July 25, 2014, LyondellBasell Industries NV (LyondellBasell) released its Q2 2014 financial results. Sales and other operating revenues stood at $12.1 billion, up 9.1% YoY while EBITDA improved 17.5% YoY to $1.9 billion. Income from continuing operations came in at $1.2 billion or $2.22 per diluted share, compared to $923 million or $1.60 per diluted share in Q2 2013. According to Jim Gallogly, CEO, LyondellBasell, the Company reported record earnings during the quarter. "Importantly, every segment contributed to this achievement. Of particular note was the strength in our Olefins and Polyolefins- Americas segment which generated nearly $1 billion of EBITDA even while we were performing significant scheduled maintenance at our La Porte ethylene site." Gallogly said. The full research reports on LyondellBasell are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/LYB/report.pdf
--
Whiting Petroleum Corp Research Reports
On July 30, 2014, Whiting Petroleum Corp. (Whiting) released its Q2 2014 and H1 2014 financial results. For Q2 2014, total revenues and other income stood at $835.6 million, up 25.9% YoY, driven by 26.7% YoY rise in Oil, NGL and natural gas sales to $825.8 million. Total production stood at 9.99 million barrels of oil equivalent (MMBOE), up 17.5% YoY. Net income available to common shareholders came in at $151.4 million or $1.26 per diluted share, compared to $134.7 million or $1.14 per diluted share in Q2 2013. For H1 2014, the Company reported total revenues and other income of $1.6 billion, up 23.4% YoY. Net income available to common shareholders came in at $260.5 million or $2.17 per diluted share, compared to $220.7 million or $1.86 per diluted share in H1 2013. For Q3 2014, the Company expects to produce between 10.50 MMBOE to 10.90 MMBOE, while for full-year 2014, the Company anticipates production in the range of 40.70 MMBOE to 41.30 MMBOE. The full research reports on Whiting are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/WLL/report.pdf
--
Albemarle Corporation Research Reports
On July 30, 2014, Albemarle Corporation (Albemarle) reported Q2 2014 and H1 2014 financial results. For Q2 2014, net sales stood at $604.7 million, up 4.8% YoY driven mainly by higher volumes in Catalysts due to strong market demand partly offset by lower Specialty Chemicals volumes in Performance Chemicals. The Company reported a loss from discontinued operations of $60.0 million versus net income from discontinued operation of $2.6 million in Q2 2013. During the quarter, net income attributable to Albemarle stood at $22.4 million or $0.28 per diluted share, compared to $82.7 million or $0.98 per diluted share in Q2 2013. For H1 2014, net sales improved 3.5% YoY to $1.2 billion while net income attributable to Albemarle came in at $79.0 million or $0.99 per diluted share, compared to $166.7 million or $1.92 per diluted share in H1 2013. The full research reports on Albemarle are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/ALB/report.pdf
--
Baker Hughes Incorporated Research Reports
On July 17, 2014, Baker Hughes Incorporated (Baker Hughes) announced its Q2 2014 and H1 2014 financial results. For Q2 2014, revenue reported at $5.9 billion, up 8.2% YoY. The Company's adjusted EPS improved 70.4% YoY to $0.92. According to Zacks, the consensus estimate for the Company's Q2 2014 revenue and adjusted EPS was c.$5.8 billion and $0.89 respectively. Net income attributable to Baker Hughes came in at $353 million or $0.80 per diluted share, compared to $240 million or $0.54 per diluted share in Q2 2013. For H1 2014, revenue improved 8.9% YoY to $11.7 billion while net income attributable to Baker Hughes came in at $681 million or $1.55 per diluted share, compared to $507 million or $1.14 per diluted share in H1 2013. The full research reports on Baker Hughes are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/BHI/report.pdf
--
Noble Energy Inc Research Reports
On July 24, 2014, Noble Energy Inc. (Noble Energy) reported Q2 2014 and H1 2014 financial results. For the quarter, the Company reported total revenues of $1.4 billion, up 20.4% YoY reflecting growth across all three segments: Crude oil and condensate, Natural gas, and Natural gas liquids. Operating profit jumped by 46.5% YoY to $529 million, while net income came in at $192 million or $0.52 per diluted share, compared to $377 million or $1.04 per diluted share in Q2 2013. For H1 2014, the Company reported total revenues of $2.8 billion, up 20.5% YoY. Net income stood at $392 million or $1.07 per diluted share, compared to $639 million or $1.76 per diluted share in H1 2013. The full research reports on Noble Energy are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/NBL/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
